Online inquiry

IVTScrip™ mRNA-Anti-C5, h5G1.1HuG2/G4(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ8076MR)

This product GTTS-WQ8076MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets C5 gene. The antibody can be applied in Dermatomyositis, Nephritis, Atypical hemolytic uremic syndrome (aHUS) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_001317163.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 727
UniProt ID P01031
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-C5, h5G1.1HuG2/G4(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ8076MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ12270MR IVTScrip™ mRNA-Anti-IL6R, MRA(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA MRA
GTTS-WQ12818MR IVTScrip™ mRNA-Anti-MASP2, OMS721(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA OMS721
GTTS-WQ11959MR IVTScrip™ mRNA-Anti-LTA, MLTA3698A(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA MLTA3698A
GTTS-WQ6722MR IVTScrip™ mRNA-Anti-EGFR, DS 1024(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA DS 1024
GTTS-WQ10930MR IVTScrip™ mRNA-Anti-APP, MABT5102A(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA MABT5102A
GTTS-WQ15200MR IVTScrip™ mRNA-Anti-TNF, TA-650(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA TA-650
GTTS-WQ11334MR IVTScrip™ mRNA-Anti-F, MEDI-524(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA MEDI-524
GTTS-WQ15776MR IVTScrip™ mRNA-Anti-CA9, WX-G250(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA WX-G250
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW